Abstract
The significance of lipid peroxidation and immune parameters to predict effectiveness of immunomodulating therapy in patients with chronic recurrent herpes infection has been assessed. It has been established that normal augmentation of second (trienic conjugates) products of lipid peroxydation in erythrocytes, levels of basal NBT-test and unchanged concentration of CD3 + 16/56 + -cells are reference predictors of favorable prognosis for the immunomodulating treatment. The predictors of unfavorable prognosis of the treatment effectiveness are increase of basal NBT-test levels, augmentation of second (trienic conjugates) аnd decreased number of CD3 + 16/56 + -lymphocytes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
